Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. The Company is developing new drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it demonstrated favorable safety and pharmacologic properties. It recently entered cancer clinical trials.
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (14-Jun-2018)
Closing share price (14-Jun-2018)
General and administrative expense
Operating expense total